Clinical case

Neuralgic amyotrophy and hepatitis E infection: 6 prospective case reports

Romain Garofoli,1 Paul Seror,2 Jennifer Zauderer,1 Alexandra Roren,1 Henri Guerini,3 François Rannou,1,4 Jean-Luc Drape,3 Christelle Nguyen,1,5,6 Marie-Martine Lefèvre-Colau1

ABSTRACT

Introduction Hepatitis E virus (HEV) represents the main cause of enterically transmitted hepatitis worldwide. It is known that neuralgic amyotrophy (NA) is one of the most frequent neurological manifestations of HEV. However, clinical, electrodiagnostic (EDX) and MRI characteristics, as well as long-term follow-up of HEV-related NA have not been fully described yet.

Case reports We describe longitudinally clinical, EDX, biological and MRI results of six cases of HEV-associated NA, diagnosed from 2012 to 2017. Patients were between the ages of 33 and 57 years old and had a positive HEV serology. Clinical patterns showed the whole spectrum of NA, varying from extensive multiple mononeuropathies damage to single mononeuropathy. EDX results showed that the patients totalised 26 inflammatory mononeuropathies (1 to 8 per patient). These involved classical nerves such as suprascapular (6/6 cases), long thoracic (5/6 cases) and accessory spinal nerves (2/6 cases) and, some less frequent more distal nerves like anterior intersosseous nerve (3/6 cases), as well as some unusual ones such as the lateral antebrachial cutaneous nerve (1/6 case), sensory fibres of median nerve (1/6 case) and phrenic nerves (1/6 case). After 2 to 8 years, all nerves had clinically recovered (muscle examination above 3/5 on MRC scale for all muscles except in one patient).

Discussion HEV should be systematically screened when NA is suspected, whatever the severity, if the onset is less than 4 months (before IgM HEV-antibodies disappear) and appears to be frequently associated with severe clinical and EDX pattern, without increasing the usual recovery time.

INTRODUCTION

Neuralgic amyotrophy (NA) or Parsonage and Turner syndrome (PTS) is a rare and under-recognised syndrome, with a sex ratio M:F of 2:1, occurring in at least 2 per 100 000 per year in a cohort of patients examined by trained physicians.2 NA is defined as (sub) acute (within hours or days) monophasic painful (numerical rating scale score ≥ 7/10) neurologic injury, with multifocal distribution involving mainly the brachial plexus, excluding a direct trauma, malignancy and local radiation, and with normal cervical spine MRI findings.2-3 It is triggered at least in 25% by viral infection6: Parvovirus B19 (PV B19), human cytomegalovirus (HCMV), herpes simplex virus (HSV), etc. In 2009, the first case of hepatitis E virus (HEV) associated NA was reported by Fong & Illahi7 and recently, some cases were reported.8 HEV represents the main cause of enterically transmitted hepatitis worldwide, being responsible for more than 50% of acute hepatitis cases in endemic developing countries.9 Transmission to humans comes mainly from eating undercooked meat of infected animals (pork, wild boar...
in particular). HEV was long considered as endemic only in developing countries, mostly South and East Asia and India but the virus is now known to be endemic in developed European countries. Indeed, Man-suy found an overall seroprevalence of 39.1% among blood donors in 2011 in the South of France, ranging from 20% to 71.3% depending on geographical area.

The association between HEV and NA remains little known and overlooked; the most described neurological manifestation associated with HEV being Guillain-Barré syndrome. Besides, clinical, electrodiagnostic (EDX) and MRI characteristics, as well as evolution of HEV-related NA have not been fully described yet.

**Case reports**

We describe (tables 1 and 2) longitudinally clinical, EDX, biological and MRI results of 6 cases of HEV-associated NA, diagnosed in our centre from February 2012 to September 2017. All clinical evaluations were performed by the same physician, and all EDX examinations were performed by the same operator, using the same protocol.

Clinical evaluation was made 1 to 3 months after symptoms onset and again 2 to 8 years later. All patients underwent cervical spine MRI to rule out a differential diagnosis of cervical nerve entrapment. All but one had bilateral scapular MRI with the following protocol: axial T1-weighted sequence and short-T1 inversion recovery (STIR) sequence in axial and coronal planes, of shoulder girdle. All participants gave an informed agreement for the use of their anonymous clinical, EDX, biological and MRI data in this study. We received a local committee approval for this study.

The 6 cases were between the ages of 33 and 57 years old (mean 44.5), sex ratio was 5 M/1 F. All patients had positive serology: IgM HEV-antibodies above normal range on Wantai test. Liver enzymes were initially increased in all cases and varied from 4 N to 200 N but went back to normal range in all cases without any treatment.

Clinical patterns showed the whole spectrum of NA, varying from extensive multiple mononeuropathy damage (5/6 cases) to single mononeuropathy. 4/6 patients had bilateral proximal and distal symptoms and 1/6 had bilateral phrenic involvement.

EDX results showed that the 6 patients totalised 26 inflammatory mononeuropathies (1 to 8 per patient). These involved classical nerves such as suprascapular (6/6 cases, twice bilaterally), long thoracic (5/6 cases) and accessory spinal nerves (2/6 cases, one bilaterally) and, some less frequent more distal nerves like anterior interosseous nerve (3/6 cases, twice bilaterally), as well as some unusual ones such as the lateral antebrachial cutaneous nerve (LABCN) (1/6 case), the sensory fibres of median nerve (1/6 case) and phrenic nerves (1/6 case bilaterally), originating from cervical plexus. At the initial examination, EDX pattern demonstrated an acute and severe axonal loss indicated for motor nerves by: a very low (compound) motor action potential amplitude (nerve conduction study), and very reduced interference pattern with high firing rate during maximal effort, with numerous fibrillations/positive sharp waves at rest (needle examination).

On scapular MRI, atrophy in at least one muscle was observed in all patients (figure 1). Out of 26 nerves involved, after 2 to 8 years, all had clinically recovered (muscle examination above 3/5 on MRC scale for all muscles except in one patient).

All patients had a cervical MRI that could not explain clinical presentation.

**DISCUSSION**

Previous authors stated that HEV-associated NA cases were more likely to be men, middle-aged, have bilateral involvement of brachial plexus (80% vs 8.6%), and a particularly high prevalence of phrenic nerve involvement was found by Van Eijk (24.5% vs 3.5%, p=0.01), along with Scanvion (18.0% vs 6.6%, p=0.028) compared with global population of NA.

In our case series, 5 out of 6 patients were male, which was consistent with a recent study that suggested a higher likelihood of HEV-associated NA in men. Indeed, Ripellino et al, in their study of 141 acute HEV infection, found out that men had higher odds (OR =5.2, CI 1.12 to 24.0, p=0.03) of developing NA after infection with HEV. An interesting fact in this study was that three couples were simultaneously infected with HEV, in which only the men developed NA.

In our case series, 3/6 patients had anterior interosseous nerve paresis, which might also induce a severe disability (in writing and fine motor control activities). This particular pattern may be overlooked and was not diagnosed in our patients before EDX was performed. Maldonado et al reported anterior interosseous nerve involvement in 3 out of 7 cases of supposed isolated long thoracic nerve palsy (HEV-status unknown). Phrenic nerve lesion is a rare condition, seems to be more frequent in HEV-associated NA and is supposed to recover more slowly than other nerves involvement in NA, because of a longer length of nerve regrowth.

Patients with bilateral symptoms, proximal and distal nerves involvement, and extensive multiple mononeuropathy, can be considered severe clinical patterns of NA. HEV-related NA appears to be frequently associated with a severe clinical and EDX pattern, without modifying the usual recovery time. In our case series, after at least 2 years of follow-up, all patients had a good clinical and electrophysiological recovery. Therefore, HEV should be systematically screened when NA is suspected, whatever the severity, if the onset is less than 3 or 4 months (before IgM HEV-antibodies disappear).

Searching for liver enzyme elevation is not systematic in case of painful upper limb palsy or NA. Furthermore, bilateral and extensive NA are frequently unrecognised, so when liver enzymes are elevated, it is often related to painkiller medication such as paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) medication (n=2
| Case Number | 1          | 2          | 3          | 4          | 5          | 6          |
|-------------|------------|------------|------------|------------|------------|------------|
| **Baseline characteristics** |            |            |            |            |            |            |
| Age         | 33         | 41         | 51         | 37         | 57         | 48         |
| Work        | Physiotherapist | Engineer | Train driver trainer | Removal man | University teacher | Winegrower |
| Body Mass Index (kg/m²) | 20.8       | 21.7       | 26.9       | 24.2       | 29.1       | 25.7       |
| Gender      | M          | M          | M          | M          | F          | M          |
| ALAT        | 200 N      | N          | N          | 16 N       | 2 N        | 10 N       |
| ASAT        | 80 N       | N          | N          | 4 N        | 4 N        | 5 N        |
| Hepatic symptoms | None     | None       | None       | Loss of weight (8 kgs) | None       | None       |
| HEV testing |            |            |            |            |            |            |
| Delay before blood testing | 15 days | 5 days | 3 months | 2 months | 3 months | 4 months |
| HEV IgM status (Wantai) | Positive | Positive | Positive | Positive | Positive | Positive |
| HEV RT-PCR | /          | Positive   | /          | Negative | Negative | Negative |
| Clinical data: |            |            |            |            |            |            |
| Pain (NRS) | 3/10       | 4/10       | 4/10       | 6/10       | 5/10       | 6/10       |
| Initial muscle motor deficiency (MRC scale) | - left IS: 1/5 | - right SA: 4/5 | - right SA: 1/5 | - right SA: 1/5 | - right SA: 2/5 | - T: right 1/5, left 3/5 |
|            | - right upper T: 4/5 | - right SSp: 4/5 | - right IS: 4/5 | - right IS: 4/5 | - IS: right 4/5, left 1/5 | - SA: right 1/5, left 4/5 |
|            | - right lower T: 1/5 | - right deltoid: 4/5 | - right deltoid: 4/5 | - right elbow flexors: 3/5 | - left T: 4/5 | - IS: right 1/5, left: 2/5 |
|            | - right deltoid: 4/5 | - right biceps: 4/5 | - right FPL: 2/5 | - left FPL/FDP2/PO: 2/5 | - right FPL/FDP/PQ: 2/5 | - right FPL: 1/5 |
|            | - right biceps: 4/5 | - right deltoid: 4/5 | - left FPL/FDP/PQ: 2/5 | - left FPL/FDP/PQ: 3/5 | - right PQ: 0/5 | - left FPL: 3/5 |
|            | - right biceps: 4/5 | - right deltoid: 4/5 | - right PQ: 0/5 | - left FPL: 3/5 | - right PQ: 0/5 | - bilateral diaphragm: orthopnoea requiring oxygen at night |
|           |            |            |            |            |            |            |
| EDX data |            |            |            |            |            |            |
| Time since onset in months | 3          | 1          | 3          | 6          | 3          | 3          |

Continued
### Table 1  Continued

| Case Number | 1 | 2 | 3 | 4 | 5 | 6 |
|-------------|---|---|---|---|---|---|
| **EDX:** importance of the initial nerve lesions | - severe left SSN | - severe right LTN | - severe right LTN | - important right LTN | - obvious right LTN | - severe right & mild left LTN |
| | - important right SAN | - moderate upper trunk of BP (C5C6C7) or C5C6C7 root entrapment | - moderate right SSN | - moderate right SSN | - obvious right sensory fibre of median nerve | - severe right & moderate left AIN |
| | - mild right SSN | | - moderate left LABCN | - mild left C7 | - severe left SSN | - severe right & moderate left AIN |
| | | | - important right & moderate left AIN | | - moderate left C7 | - severe right & moderate left AIN |
| | | | | | - important right & moderate left AIN | - severe right bilat SSN |
| | | | | | - severe right bilat SAN | - severe right bilat PN |
| | | | | | - severe right bilat PN | |

**MRI data**

| Cervical MRI data | No radicular impingement | Narrowing of the cervical spine canal | No radicular impingement | Left C7 impingement | No radicular impingement |
|-------------------|--------------------------|-----------------------------------|--------------------------|---------------------|--------------------------|
| Time since onset  | 3 years                  | 6 months                          | 8 months                 | 6 months           | 10 months               |

**Scapular MRI data**

| Scapular MRI | / | 3 years | / | hyperT1*: right SA | hyperT2: right TM | HyperT2 Dixon: right SA/Deltoid |
|--------------|---|---------|---|-------------------|------------------|-------------------------------|
|              | / |          | / | - amyotrophy right SA | - amyotrophy right SA/Deltoid/TM/BB/IS/SSc | - amyotrophy: right SA/Deltoid/ |
|              |   |         |   |                   |                   | IS/SSp                        |
|              |   |         |   |                   |                   | HyperT2 Dixon: PQ/FDP/AM on left arm MRI |
|              |   |         |   |                   |                   | - amyotrophy: both SA           |
|              |   |         |   |                   |                   | - hyperT2: left IS/SSp          |
|              |   |         |   |                   |                   | - amyotrophy: left IS/SSp       |
|              |   |         |   |                   |                   | - hyperT2 Dixon: both T, left IS, right SA |
|              |   |         |   |                   |                   | - amyotrophy: both SSp          |

*HyperT1 signal: muscle fatty infiltration.
†HyperT2 Dixon signal: muscle oedema.
/ Missing data.

AM, Anconaeal muscle; ASAT, Aspartate aminotransferase; ALAT, Alanine aminotransferase; AIN, Anterior interosseous nerve; BP, Brachial plexus; bilat, bilateral, CMAP, Compound motor action potential; FPL: flexor pollicis longus; FDP2, Flexor digitorum profundus of digit 2; HEV, Hepatitis E virus; IS, Infraspinatus; LTN, Long thoracic nerve; LABCN, Lateral antebrachial cutaneous nerve; NRS, Numeric rating scale; PQ: Pronator quadratus; PN, Phrenic nerve; RT-PCR, reverse transcription POR; SSN, Suprascapular nerve; SAN, Spinal accessory nerve; SA, Serratus anterior; SSp, Supraspinatus; T, Trapezius.
Table 2  Follow up clinical and EDX data, presented from the mildest to the severest

| Case Number | 1 | 2 | 3 | 4 | 5 | 6 |
|-------------|---|---|---|---|---|---|
| Follow up data | | | | | | |
| Clinical data: | | | | | | |
| Time after onset | 8 years | 4 years | 2 years | 3 years | 3 years | 2.5 years |
| Pain (NRS) | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| Muscle motor deficiency | - left IS: 5/5 | Complete recovery: all muscles 5/5 | - right IS: 5/5 | Complete recovery: all muscles 5/5 | - right SA: 4/5 | - bilat T: 5/5 |
| | | | - right SS: 4/5 | | - bilat IS: 4/5 | - SA: right 5/5, left: 4/5 |
| | | | - right deltoid: 5/5 | | - right FPL/FDP/PQ: 3/5 | - SA: right 5/5 |
| | | | - right elbow flexors/biceps: 4/5 | | - left FPL/FDP/PQ: 5/5 | - right PQ: 4/5 |
| | | | | | | - left PQ: 5/5 |
| | | | | | | - bilat diaphragm; orthopnoea improved but still requiring oxygen at night |
| EDX data: | | | | | | |
| Time after onset | 8 years | 3.5 years | 2 years | 3 years | 3 years | 2.5 years |
| EDX | / | - normal interference pattern for deltoid, biceps and trapezius | - outstanding increase of motor units number and of CMAP amplitude for SA | / | - very good increase of motor units number and collateral reinnervation in left PQ, right SA and right IS | - normal pattern in both T and right PQ |
| | the patient was evaluated in our centre but didn’t want to perform a new EDX as he felt totally fine | - very good increase of motor units number with collateral reinnervation and of CMAP amplitude for SA, IS, T; PQ | / | - excellent increase of motor units number with direct and collateral reinnervation; with normal CMAP amplitude for right SA, and both IS | - 50% recovery of PN |
| | | - recovery limited by concomitant C6C7 root entrapment | the patient was evaluated in our centre but didn’t want to perform a new EDX as he felt totally fine | | |

*HyperT1 signal: muscle fatty infiltration.
†HyperT2 Dixon signal: muscle oedema.
/ Missing data.
AIN, Anterior interosseous nerve; AM, Anconeal muscle; bilat, Bilateral; CMAP, Compound motor action potential; IS, Infraspinatus; FPL, Flexor pollicis longus; FDP2, Flexor digitorum profundus of digit 2; LABCN, Lateral antebrachial cutaneous nerve; LTN, Long thoracic nerve; PQ, Pronator quadratus; PN, Phrenic nerve; SSN, Suprascapular nerve; SAN, Spinal accesssory nerve; SA, Serratus anterior; SS, Supraspinatus; T, Trapezius.

**Garofoli R, et al. RMD Open 2020;6:e001401. doi:10.1136/rmdopen-2020-001401.**
in our case series), before considering a potential relation with HEV and especially HEV-associated NA. Of note, liver enzyme elevation was first related to paracetamol or AINS medication in two cases, before hepatitis E was diagnosed. In our case series, only 1 patient was viremic: the only one that had been tested within 10 days of the onset of HEV infection. This is consistent with larger studies, highlighting the interest in early testing for HEV in case of NA.19

The main limitations of our study include reporting cases seen in a tertiary centre, which might be more severe than usual HEV-associated NA, and not including functional criteria in the assessment of our patients. This was not the goal of our work but limitation of activity, evaluated by functional criteria should be investigated in further studies. Indeed, having a pain of 0 associated with a MRC score of 5 does not mean a full recovery because some patients might experience early fatigability and some might have changed their habits or even their work.

Acknowledgements The authors wish to thank Julianne Ruets for her help regarding English language usage.

Contributors All authors were involved in drafting the manuscript or revising it critically, and approved the final version. RG had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Study design: JZ, PS, AR, MMLC. Data Collection: JZ, PS, AR, MMLC.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval We received local committee approval for this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID id
Romain Garofoli http://orcid.org/0000-0003-3788-819X

REFERENCES
1 van Allen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev 2009:8.
2 van Allen N, van Eijk JJ, Ennik T, et al. Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting: a prospective cohort study. PLoS One 2015;10:e0128361.
3 van Allen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 2006;129:438–50.
4 Seror P, Lenglet T, Nguyen C, et al. Unilateral winged scapula: clinical and electrodiagnostic experience with 128 cases, with special attention to long thoracic nerve palsy: winged scapula and LTN palsy. Muscle Nerve 2018;56:193–20.
5 Seror P. Neuralgic amyotrophy, an update. Joint Bone Spine 2017;84:153–8.
6 Van Eijk JJ, Groothuis JT, Van Allen N, et al. Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment: neuralgic amyotrophy update. Muscle Nerve 2016;53:337–50.
7 Fong F, Illahi M. Neuralgic amyotrophy associated with Hepatitis E virus. Clin Neurol Neurosurg 2009;111:193–5.
8 Scanvion Q, Perez T, Cassim F, et al. Neuralgic amyotrophy triggered by Hepatitis E virus: a particular phenotype. J Neurol 2017;264:770–80.
9 Lapa D, Capobianchi MR, Garbuglia AR, et al. Epidemiology of Hepatitis E virus in European countries. Int J Mol Sci 2015;10:25711–43.
10 Kamar N, Bendall R, Legrand-Abравanel F, et al. Hepatitis E. Lancet 2012;379:2477–88.
11 Dalton HR, Bendall R, Iazz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698–9.
12 Mansuy JM, Saune K, Rech H, et al. Seroprevalence in blood donors reveals widespread, multi-source exposure to hepatitis E virus, southern France, October 2011. Euro Surveill 2015;20:27–34.
13 Gaskin CM, Helms CA. Parsonage-turner syndrome: MR imaging findings and clinical information of 27 patients. Radiology 2006;240:501–7.
14 Nguyen C, Guerini H, Zauderer J, et al. Magnetic resonance imaging of dynamic scapular winging secondary to a lesion of the long thoracic nerve. Joint Bone Spine 201. 2016;83:747–9.
15 Seror P, Kunz TP, Maisonde T. Sensory nerve action potential abnormalities in neuralgic amyotrophy: a report of 18 cases. J Clin Neuromuscul Dis 2002;4:45–9.
16 Seror P. Isolated sensory manifestations in neuralgic amyotrophy: report of eight cases. Muscle Nerve 2004;29:134–8.
17 van Eijk JJJ, Dalton HR, Ripellino P, et al. Clinical phenotype and outcome of Hepatitis E virus: associated neuralgic amyotrophy. Neurology 2017;89:909–17.
18 Maldonado AA, Zuckerman SL, Howe BM, et al. ‘Isolated long thoracic nerve palsy’: more than meets the eye. J Plast Reconstr Aesthet Surg 2017;70:1272–79.
19 Ripellino P, Pasi E, Meli G, et al. Neurologic complications of acute hepatitis E virus infection. Neurol Neuroimmunol Neuroinflamm 2019;5.
20 Blasco-Perrin H, Madden RG, Stanley A, et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French Study. Aliment Pharmacol Ther 2015;42:574–81.